115 related articles for article (PubMed ID: 16952875)
1. Liposome-based systems for anti-tumor vaccination: influence of lipopeptide adjuvants.
Heurtault B; Thomann JS; Jedrzejewska J; Wels WS; Schuber F; Frisch B
J Liposome Res; 2006; 16(3):205-13. PubMed ID: 16952875
[TBL] [Abstract][Full Text] [Related]
2. Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct.
Roth A; Rohrbach F; Weth R; Frisch B; Schuber F; Wels WS
Br J Cancer; 2005 Apr; 92(8):1421-9. PubMed ID: 15812545
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.
Thomann JS; Heurtault B; Weidner S; Brayé M; Beyrath J; Fournel S; Schuber F; Frisch B
Biomaterials; 2011 Jul; 32(20):4574-83. PubMed ID: 21474175
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of thiol-reactive lipopeptide adjuvants. Incorporation into liposomes and study of their mitogenic effect on mouse splenocytes.
Roth A; Espuelas S; Thumann C; Frisch B; Schuber F
Bioconjug Chem; 2004; 15(3):541-53. PubMed ID: 15149182
[TBL] [Abstract][Full Text] [Related]
5. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer.
Shariat S; Badiee A; Jalali SA; Mansourian M; Yazdani M; Mortazavi SA; Jaafari MR
Cancer Lett; 2014 Dec; 355(1):54-60. PubMed ID: 25224570
[TBL] [Abstract][Full Text] [Related]
6. Effect of synthetic lipopeptides formulated in liposomes on the maturation of human dendritic cells.
Espuelas S; Roth A; Thumann C; Frisch B; Schuber F
Mol Immunol; 2005 Apr; 42(6):721-9. PubMed ID: 15781116
[TBL] [Abstract][Full Text] [Related]
7. Optimization of peptide-based cancer vaccine compositions, by sequential screening, using versatile liposomal platform.
Jacoberger-Foissac C; Saliba H; Seguin C; Brion A; Kakhi Z; Frisch B; Fournel S; Heurtault B
Int J Pharm; 2019 May; 562():342-350. PubMed ID: 30880104
[TBL] [Abstract][Full Text] [Related]
8. Design of highly immunogenic liposomal constructs combining structurally independent B cell and T helper cell peptide epitopes.
Boeckler C; Dautel D; Schelté P; Frisch B; Wachsmann D; Klein JP; Schuber F
Eur J Immunol; 1999 Jul; 29(7):2297-308. PubMed ID: 10427993
[TBL] [Abstract][Full Text] [Related]
9. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees.
BenMohamed L; Gras-Masse H; Tartar A; Daubersies P; Brahimi K; Bossus M; Thomas A; Druilhe P
Eur J Immunol; 1997 May; 27(5):1242-53. PubMed ID: 9174617
[TBL] [Abstract][Full Text] [Related]
10. Synthetic lipopeptides incorporated in liposomes: in vitro stimulation of the proliferation of murine splenocytes and in vivo induction of an immune response against a peptide antigen.
Fernandes I; Frisch B; Muller S; Schuber F
Mol Immunol; 1997 Jun; 34(8-9):569-76. PubMed ID: 9393959
[TBL] [Abstract][Full Text] [Related]
11. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide.
Kızılbey K; Mansuroğlu B; Derman S; Mustafaeva Akdeste Z
Bioengineered; 2018 Jan; 9(1):134-143. PubMed ID: 28910565
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice.
Iwama T; Uchida T; Sawada Y; Tsuchiya N; Sugai S; Fujinami N; Shimomura M; Yoshikawa T; Zhang R; Uemura Y; Nakatsura T
Biochem Biophys Res Commun; 2016 Jan; 469(1):138-143. PubMed ID: 26616051
[TBL] [Abstract][Full Text] [Related]
13. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN.
Mansourian M; Badiee A; Jalali SA; Shariat S; Yazdani M; Amin M; Jaafari MR
Immunol Lett; 2014 Nov; 162(1 Pt A):87-93. PubMed ID: 25086399
[TBL] [Abstract][Full Text] [Related]
14. Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study.
Le Gal FA; Prevost-Blondel A; Lengagne R; Bossus M; Farace F; Chaboissier A; Gras-Masse H; Engelhard VH; Guillet JG; Gahéry-Ségard H
Int J Cancer; 2002 Mar; 98(2):221-7. PubMed ID: 11857412
[TBL] [Abstract][Full Text] [Related]
15. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides.
Franke ED; Corradin G; Hoffman SL
J Immunol; 1997 Oct; 159(7):3424-33. PubMed ID: 9317141
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of liposomes containing lipid core peptides and the adjuvant Quil A.
White K; Rades T; Kearns P; Toth I; Hook S
Pharm Res; 2006 Jul; 23(7):1473-81. PubMed ID: 16779706
[TBL] [Abstract][Full Text] [Related]
17. Liposomal constructs for antitumoral vaccination by the nasal route.
Kakhi Z; Frisch B; Heurtault B; Pons F
Biochimie; 2016 Nov; 130():14-22. PubMed ID: 27423321
[TBL] [Abstract][Full Text] [Related]
18. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
19. Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model.
Alipour Talesh G; Ebrahimi Z; Badiee A; Mansourian M; Attar H; Arabi L; Jalali SA; Jaafari MR
Immunol Lett; 2016 Aug; 176():57-64. PubMed ID: 27260485
[TBL] [Abstract][Full Text] [Related]
20. Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation.
Krup OC; Kroll I; Böse G; Falkenberg FW
J Immunother; 1999 Nov; 22(6):525-38. PubMed ID: 10570751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
